List of Excipients in Branded Drug PENTASA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Takeda Pharmaceuticals America Inc	PENTASA	mesalamine	54092-189	CASTOR OIL
Takeda Pharmaceuticals America Inc	PENTASA	mesalamine	54092-189	D&C YELLOW NO. 10
Takeda Pharmaceuticals America Inc	PENTASA	mesalamine	54092-189	DIACETYLATED MONOGLYCERIDES
Takeda Pharmaceuticals America Inc	PENTASA	mesalamine	54092-189	ETHYLCELLULOSE
Takeda Pharmaceuticals America Inc	PENTASA	mesalamine	54092-189	FD&C BLUE NO. 1
Takeda Pharmaceuticals America Inc	PENTASA	mesalamine	54092-189	FD&C GREEN NO. 3

Pentasa Excipient Strategy and Commercial Opportunities in Mesalamine Modified-Release Products

Last updated: September 6, 2026

Pentasa is a mesalamine multiparticulate modified-release product designed to deliver 5-aminosalicylic acid throughout the gastrointestinal tract. Its commercial value is tied less to mesalamine itself, whose basic composition-of-matter protection has long expired, and more to release control, excipient selection, dose flexibility, manufacturing consistency, and regulatory differentiation.

The strongest opportunity is a platform that preserves Pentasa’s pH-independent or broadly distributed intestinal release while improving swallowability, pediatric administration, stability, adherence, or cost of goods. New excipient claims may support limited patent protection, but regulatory exclusivity and commercial differentiation will depend on clinically meaningful product advantages.

What is Pentasa and how does its excipient system work?

Pentasa contains mesalamine, also known as 5-aminosalicylic acid, for the treatment of ulcerative colitis. The U.S. product is supplied as controlled-release capsules containing mesalamine in coated microgranules. FDA labeling describes release throughout the gastrointestinal tract rather than relying solely on colonic pH conditions. [1]

The core formulation strategy is based on multiparticulate delivery:

Formulation element	Commercial function
Mesalamine	Local anti-inflammatory active ingredient
Coated microgranules	Distribute drug release across the gastrointestinal tract
Ethylcellulose or comparable water-insoluble polymer	Controls fluid penetration and drug diffusion
Povidone	Supports granule formation and coating or binder performance
Talc	Processing aid and anti-tacking agent in coating systems
Magnesium stearate	Lubricant for manufacturing
Gelatin capsule shell	Oral unit-dose presentation

The exact excipient composition varies by market and presentation. The U.S. prescribing information identifies the controlled-release microgranule architecture and lists inactive ingredients for the approved capsule product. [1] European product information describes prolonged-release granules and market-specific presentations. [2]

Why multiparticulate delivery matters

Multiparticulate systems can reduce the effect of gastric emptying and intestinal transit on drug exposure. Individual microgranules disperse through the gastrointestinal contents, which can create more consistent distribution than a single monolithic tablet.

For mesalamine, the formulation objective is local exposure at the intestinal mucosa rather than high systemic concentrations. The excipient system therefore must control:

• Water ingress.
• Polymer permeability.
• Drug diffusion.
• Granule integrity.
• Release under variable gastrointestinal pH.
• Dose uniformity across capsules or sachets.

This release profile differentiates Pentasa from some mesalamine products that depend more heavily on pH-triggered coatings.

What excipients are protected by Pentasa patents?

Pentasa’s principal commercial protection historically came from formulation and controlled-release technology rather than a new chemical entity patent. The relevant intellectual-property categories include:

1. Controlled-release mesalamine microgranules.
2. Coating systems based on water-insoluble polymers.
3. Multiparticulate dosage forms.
4. Release across selected gastrointestinal regions.
5. Manufacturing processes for coating, drying, blending, and encapsulation.
6. Dosage regimens for inflammatory bowel disease.

The original formulation patents are old relative to current pharmaceutical patent terms. Any remaining U.S. protection would need to be assessed against the specific patent listed for the relevant NDA, terminal disclaimers, patent-term adjustments, pediatric extensions, and Orange Book status. The FDA Orange Book is the controlling public source for listed patents and regulatory exclusivity associated with approved small-molecule products. [3]

Can a new excipient combination obtain patent protection?

Yes, but a new patent requires more than substituting one conventional excipient for another. A defensible patent position would normally require a specific formulation combination or process linked to an unexpected technical result, such as:

• A defined coating thickness that produces a reproducible release window.
• Improved stability under elevated humidity.
• Reduced dose dumping after alcohol exposure.
• Lower variability between fed and fasted conditions.
• Improved granule strength during capsule filling.
• Reduced interaction between mesalamine and reactive excipients.
• A smaller capsule at equivalent dose.
• Reliable dispersion in water or soft food.

A patent covering only the use of common excipients in conventional amounts would face substantial obviousness risk.

When does Pentasa lose exclusivity?

Pentasa’s basic small-molecule exclusivity has expired in the United States. Mesalamine is an established active ingredient, and the commercial dispute has shifted from active-ingredient exclusivity to formulation equivalence, regulatory substitution, manufacturing capability, and product differentiation.

Protection category	Pentasa position
Active ingredient	Expired or no longer commercially decisive
Original controlled-release technology	Historically important; core terms are generally old
FDA new-drug exclusivity	Expired
Orange Book-listed formulation patents	Must be checked against the current FDA listing for the applicable NDA
Generic entry	Available or possible through abbreviated approval pathways, subject to product-specific requirements
New formulation protection	Available only for genuinely differentiated technology

A generic applicant may challenge listed patents through a Paragraph IV certification. The applicant must assert that the patent is invalid, unenforceable, or will not be infringed. FDA approval timing may be affected by a 30-month stay if the brand company files patent litigation within the statutory period. [4]

What is the Orange Book status of Pentasa?

Pentasa is an FDA-approved mesalamine product associated with NDA 019651. The Orange Book identifies approved products, patent information, therapeutic-equivalence ratings, and exclusivity data for listed drug products. [3]

Orange Book analysis should distinguish among:

• Pentasa controlled-release capsules.
• Other mesalamine delayed-release tablets.
• Mesalamine rectal suppositories or enemas.
• Generic extended-release capsules.
• Products using different release mechanisms.

Therapeutic equivalence is product-specific. A mesalamine delayed-release tablet is not automatically substitutable for a Pentasa controlled-release capsule merely because both contain mesalamine. Dosage form, release mechanism, strength, route, and FDA therapeutic-equivalence rating control substitution.

What formulation patents could protect a next-generation Pentasa product?

The most valuable patent opportunities are likely to involve a measurable clinical or manufacturing advantage.

Pediatric and geriatric formulations

A granule or sachet product that can be administered without swallowing a capsule could expand use in children, older adults, and patients with dysphagia. Potential claims could cover:

• Dry granules for sprinkling on soft food.
• Water-dispersible granules.
• Low-dust sachet contents.
• Taste-masked mesalamine particles.
• Stable suspensions prepared immediately before use.
• Dose-partitioning systems for weight-based dosing.

Taste masking is technically difficult because mesalamine can produce an unpleasant sensory profile. Polymer coating, lipid barriers, ion-exchange approaches, and multiparticulate layering could be used, but the system must preserve intestinal release.

Lower-pill-burden products

Ulcerative colitis patients often require high daily mesalamine doses. A higher-strength capsule or sachet could reduce pill burden, provided the formulation maintains dose uniformity and release performance.

The commercial constraint is manufacturing. Larger drug loads can increase:

• Capsule size.
• Granule friability.
• Coating time.
• Content-uniformity risk.
• Dissolution variability.
• Packaging requirements.

Stability-enhanced formulations

Mesalamine can present formulation-development challenges related to oxidation, discoloration, moisture, and interaction with excipients. A differentiated product could use:

• Low-moisture excipient systems.
• Oxygen-limiting packaging.
• Antioxidant-compatible formulations.
• Improved polymer barriers.
• Desiccant-containing unit-dose packs.
• Light-protective packaging.

A patent should focus on a defined stability result rather than a general claim to moisture protection.

Which excipients are commercially attractive for mesalamine products?

Ethylcellulose

Ethylcellulose is commercially relevant because it can create diffusion-controlled coatings and support pH-independent release. Its limitations include solvent or dispersion processing, coating uniformity, and scale-up control.

Hypromellose and related cellulose polymers

Hypromellose can support matrix or film-coating systems. It may enable aqueous processing and different release kinetics from ethylcellulose. The main development issue is achieving the desired mesalamine release without excessive swelling or delayed liberation.

Methacrylate copolymers

Enteric or pH-responsive methacrylate polymers can target distal intestinal release. They may produce a product that competes more directly with delayed-release mesalamine products than with Pentasa’s broader gastrointestinal release profile.

Povidone and copovidone

These excipients can improve granulation and coating adhesion. Their use must be controlled because binder level affects granule porosity, dissolution, and manufacturing throughput.

Microcrystalline cellulose

Microcrystalline cellulose can support granule structure and flow. It is attractive for dose uniformity but may increase bulk volume and affect disintegration.

Lipid and wax-based excipients

Lipid barriers can support sustained release and taste masking. Their disadvantages include polymorphism, storage sensitivity, manufacturing complexity, and possible dissolution variability.

How strong is the Pentasa patent estate?

The remaining commercial strength of the Pentasa estate is likely moderate to weak for the original product and potentially stronger for narrowly defined improvements.

Factor	Assessment
Active ingredient protection	Very weak; mesalamine is generic
Original formulation protection	Limited by age and expiration history
Manufacturing know-how	Potentially meaningful, especially for coating and scale-up
Regulatory substitution barrier	Moderate because mesalamine products use different release technologies
New formulation opportunity	Moderate to strong if supported by clinical or performance data
Litigation leverage	Depends on current Orange Book listings and claim scope
Biosimilar barrier	Not applicable; Pentasa is a small-molecule product

The most defensible asset may be manufacturing know-how rather than broad composition claims. Coating uniformity, in-process controls, particle-size distribution, and dissolution specifications can create practical barriers even when patent protection is limited.

What generic entry risks exist for Pentasa?

Generic entrants face a product-specific development burden. They must demonstrate pharmaceutical equivalence and bioequivalence or satisfy FDA requirements applicable to the reference product. The key risks include:

• Matching multiparticulate release behavior.
• Demonstrating batch-to-batch dissolution consistency.
• Controlling granule size and coating thickness.
• Managing capsule content uniformity.
• Establishing stability across climatic zones.
• Avoiding patent infringement.
• Securing reliable supplies of pharmaceutical-grade coating materials.

Generic competition may erode price without fully displacing the brand if physicians value established release performance, if formularies distinguish products, or if patients experience differences among mesalamine formulations.

What commercial opportunities exist beyond the original Pentasa capsule?

Unit-dose sachets

Sachets can improve adherence and enable direct administration of granules. They also create opportunities for differentiated packaging, dose combinations, and pediatric positioning.

Sprinkle formulations

A sprinkle product could address patients who cannot swallow capsules. The formulation must preserve granule integrity when mixed with applesauce, yogurt, or other soft foods.

Combination adherence packs

Mesalamine therapy is often chronic. Packaging that organizes daily doses, supports refill adherence, or combines oral and rectal therapy may have commercial value, although packaging claims are generally easier to protect through design, trademark, or trade-secret strategies than through strong pharmaceutical composition patents.

Global-market products

European and other international markets may favor prolonged-release granules, sachets, or alternative strengths. A single multiparticulate platform could support geographic expansion if the release profile, excipient acceptability, and labeling requirements are adapted by jurisdiction.

Contract development and manufacturing

Companies with high-throughput fluid-bed coating, extrusion-spheronization, or precision granulation capabilities could offer development and manufacturing services to generic or specialty-pharma sponsors. The technical barrier is process reproducibility, not the availability of mesalamine.

What litigation and settlement issues affect Pentasa?

Pentasa-related litigation risk centers on formulation patents, generic approval, patent certifications, and market-entry timing. A Paragraph IV challenge can trigger patent litigation and a potential 30-month FDA stay under the Hatch-Waxman framework. [4]

Settlement analysis should examine:

• Whether the brand company grants an agreed launch date.
• Whether the generic receives an authorized-generic supply arrangement.
• Whether the agreement includes restrictions on alternative formulations.
• Whether the Federal Trade Commission reviews the settlement.
• Whether later-filed formulation patents create additional litigation risk.

Because core mesalamine patents are old, future disputes are more likely to involve specific release mechanisms, manufacturing processes, or newly developed dosage forms than the active ingredient.

How does Pentasa compare with other mesalamine products?

Product type	Release strategy	Main competitive advantage	Main weakness
Pentasa controlled-release capsules or granules	Multiparticulate, broad gastrointestinal release	Distributed mesalamine delivery	More complex manufacturing
Delayed-release mesalamine tablets	pH-dependent enteric release	Established tablet manufacturing	Release may depend on intestinal pH
Extended-release mesalamine tablets	Delayed or extended release depending on product	Reduced dosing frequency	Product performance varies by technology
Rectal mesalamine	Local distal-colon delivery	High local exposure in proctitis or left-sided disease	Administration burden
Combination oral and rectal therapy	Dual-site treatment	Broader disease coverage	Higher treatment complexity

Pentasa’s most relevant differentiation is the multiparticulate release platform. A new product should not compete solely on ingredient identity or milligram strength. It should target adherence, administration, release reproducibility, or total treatment cost.

Key Takeaways

• Pentasa is a mesalamine multiparticulate controlled-release product whose value depends on release engineering rather than active-ingredient exclusivity.
• The core commercial formulation uses coated microgranules and excipients such as release-controlling polymers, binders, processing aids, and lubricants.
• Original broad formulation protection is constrained by the age of the product and expired exclusivity.
• The strongest new patent opportunities involve pediatric dosing, sprinkle administration, taste masking, stability, reduced pill burden, and manufacturing improvements.
• FDA Orange Book analysis must be performed at the specific NDA, dosage-form, and strength level.
• Paragraph IV litigation remains possible for listed patents, but generic entrants face substantial technical requirements in matching multiparticulate dissolution behavior.
• Biosimilar risk does not apply because Pentasa is a small-molecule mesalamine product.
• Commercial opportunities are strongest in sachets, pediatric and dysphagia-friendly presentations, higher-strength doses, global prolonged-release products, and contract manufacturing.

FAQs About Pentasa Excipient Strategy and Commercial Opportunities

Can Pentasa be reformulated as a liquid?

Yes. A liquid or extemporaneously prepared suspension could target pediatric and dysphagia populations, but the formulation must preserve mesalamine stability, dose uniformity, taste acceptability, and the intended intestinal release profile.

Is ethylcellulose essential to Pentasa?

Ethylcellulose is associated with controlled-release coating strategies, but it is not necessarily the only technically viable polymer. Hypromellose, methacrylate polymers, lipid barriers, and polymer combinations could produce alternative release profiles.

Does a mesalamine generic need to use the same excipients as Pentasa?

No. A generic applicant generally must demonstrate the required pharmaceutical equivalence and bioequivalence or satisfy the applicable FDA approval standard. It does not necessarily need to duplicate every inactive ingredient.

Can a company patent a new Pentasa coating process?

Yes, if the process is novel and non-obvious and produces a technically meaningful result, such as improved coating uniformity, lower solvent use, increased throughput, or better dissolution consistency.

Is Pentasa exposed to biosimilar competition?

No. Pentasa contains mesalamine, a chemically synthesized small molecule. Competitive exposure comes from generic and follow-on mesalamine products, not biosimilars.

References

1. U.S. Food and Drug Administration. (2023). Pentasa (mesalamine) controlled-release capsules: Prescribing information. FDA/DailyMed.

2. European Medicines Agency. (n.d.). Pentasa: Product information. EMA.

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.

4. U.S. Food and Drug Administration. (2024). Hatch-Waxman amendments and abbreviated new drug applications. FDA.